MarketCap
Facebook
X
TelegramAnnual report 2023
added 12-27-2025
Biophytis SA Cash and Cash Equivalents 2011-2026 | BPTS
Annual Cash and Cash Equivalents Biophytis SA
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.57 M | 11.1 M | 23.9 M | 5.85 M | 6.34 M | 14.4 M | 19.9 M | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23.9 M | 5.57 M | 12.4 M |
Quarterly Cash and Cash Equivalents Biophytis SA
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 23.9 M | - | - | - | 5.85 M | - | - | - | 6.34 M | - | - | - | 14.4 M | - | - | - | 19.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 23.9 M | 5.85 M | 14.1 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alterity Therapeutics Limited
ATHE
|
34.8 M | $ 3.6 | 4.96 % | $ 8.66 B |  Australia |
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Atara Biotherapeutics
ATRA
|
25 M | $ 6.88 | 33.08 % | $ 51.5 M |  USA |
 |
BridgeBio Pharma
BBIO
|
570 M | $ 65.8 | 0.67 % | $ 12.6 B | USA |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
AbCellera Biologics
ABCL
|
129 M | $ 3.52 | 1.88 % | $ 1.05 B |  Canada |
 |
Biogen
BIIB
|
3.01 B | $ 187.79 | 1.5 % | $ 27.5 B | USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Benitec Biopharma
BNTC
|
97.7 M | $ 12.61 | 11.02 % | $ 519 M | USA |
 |
BioXcel Therapeutics
BTAI
|
29.9 M | $ 1.76 | 18.92 % | $ 4.46 M | USA |
 |
Burford Capital Limited
BUR
|
322 M | $ 8.25 | 6.25 % | $ 1.31 B |  Britain |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
BeyondSpring
BYSI
|
110 M | $ 1.46 | 0.92 % | $ 58.9 M | USA |
 |
Annovis Bio
ANVS
|
5.75 M | $ 2.57 | 3.63 % | $ 23.2 M | USA |
 |
Cabaletta Bio
CABA
|
193 M | $ 3.29 | 3.63 % | $ 3.84 M | USA |
 |
Catalyst Biosciences
CBIO
|
33.5 M | $ 12.08 | 0.04 % | $ 795 M | USA |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M | Britain |
 |
C4 Therapeutics
CCCC
|
74.6 M | $ 3.54 | 16.28 % | $ 293 M | USA |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
118 M | - | 4.14 % | $ 49.1 M | USA |
 |
Codexis
CDXS
|
19.3 M | $ 1.27 | 3.25 % | $ 93.2 M | USA |
 |
Cerus Corporation
CERS
|
20 M | $ 1.95 | 0.78 % | $ 372 M | USA |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
Cullinan Management
CGEM
|
83 M | $ 15.42 | -2.03 % | $ 902 M | USA |
 |
Coherus BioSciences
CHRS
|
103 M | $ 1.93 | 5.77 % | $ 182 M | USA |
 |
ADC Therapeutics SA
ADCT
|
326 M | $ 4.15 | 1.22 % | $ 105 M |  Schweiz |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Celldex Therapeutics
CLDX
|
28.9 M | $ 31.55 | 7.2 % | $ 2.1 B | USA |
 |
Cellectis S.A.
CLLS
|
143 M | $ 3.59 | 0.7 % | $ 116 M |  France |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M | Canada |
 |
Cellectar Biosciences
CLRB
|
13.2 M | $ 2.87 | 3.99 % | $ 7.49 M | USA |
 |
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | Canada |
 |
Collegium Pharmaceutical
COLL
|
231 M | $ 37.35 | 0.15 % | $ 1.18 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
120 M | $ 33.98 | 0.32 % | $ 3.53 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
709 M | $ 24.73 | 2.02 % | $ 3.02 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
13.7 M | $ 9.56 | 19.35 % | $ 41.4 M | USA |
 |
Applied Therapeutics
APLT
|
49.9 M | - | - | $ 8.42 M | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Atea Pharmaceuticals
AVIR
|
95.7 M | $ 6.14 | 4.16 % | $ 500 M | USA |
 |
Cardiff Oncology
CRDF
|
17.5 M | $ 2.01 | 6.65 % | $ 134 M | USA |